<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739219</url>
  </required_header>
  <id_info>
    <org_study_id>CP00006</org_study_id>
    <nct_id>NCT00739219</nct_id>
  </id_info>
  <brief_title>Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)</brief_title>
  <acronym>Outcomes</acronym>
  <official_title>Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO) Using the Apieron NO Analyzer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apieron</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apieron</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to show that pharmacotherapy guided by eNO and clinical standard of
      care produces a superior outcome to trial-based therapy guided by clinical standard of care
      alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with persistent, moderate to severe asthma will be randomized to receive therapy
      guided by either eNO and clinical standard of care (eNO group) or clinical standard of care
      (control group). An eNO treatment algorithm will be established for each patient in the eNO
      group at Baseline (Visit 1). Enrollment is estimated to be six months with a follow up period
      of twelve months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to lack of care guidelines in the protocol.
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma control days</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>eNO group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>eNO measurement is used to inform asthma management decisions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Asthma is managed according to existing standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Apieron Insight eNO monitor</intervention_name>
    <description>The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.</description>
    <arm_group_label>eNO group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-existing diagnosis of asthma

          -  Persistent, moderate or severe asthma as classified by NAEPP

          -  Sub-optimally controlled asthma

          -  Initiated ICS therapy for at least the past 30 days and a history of improvement of
             asthma control on steroids

        Exclusion Criteria:

          -  Active cigarette smoking or â‰¥ 10 pack-years smoking history

          -  Xolair taken in the past 6 months prior to enrollment

          -  Oral prednisone taken in the last 4 weeks prior to enrollment

          -  Cystic Fibrosis, COPD, ciliary dyskinesia, chest wall deformities or scoliosis

          -  Subject is currently enrolled in another investigational drug study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E Berger, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of Santa Clara Valley Research Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of Hartford</name>
      <address>
        <city>Glastonbury</city>
        <state>Connecticut</state>
        <zip>06033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Center of Chicago, S.C.</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Asthma- Allergy Clinic&amp; Research Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Clinical Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center, LLC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Allergy and Asthma</name>
      <address>
        <city>Highland Park</city>
        <state>New Jersey</state>
        <zip>08904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Allergy Associates P.A.</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Dermatology Research Center, LLC</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Research Associates</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research &amp; Consulting, Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>January 19, 2009</last_update_submitted>
  <last_update_submitted_qc>January 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Nina Peled, VP of Regulatory and Clinical Affairs</name_title>
    <organization>Apieron</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>inflammation</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>eNO</keyword>
  <keyword>FENO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

